Superiority of ArTiMist Versus Quinine in Children With Severe Malaria

Plasmodium Falciparum Malaria Clinical Trial

Official title:

A Phase III, Randomised, Open Labelled, Active Controlled, Multi Centre, Superiority Trial of ArTiMist™ Versus Intravenous Quinine in Children With Severe or Complicated Falciparum Malaria, or Uncomplicated Falciparum Malaria With Gastrointestinal Complications.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01258049
• Other study ID #: ART004
• Status: Completed
• Phase: Phase 3
• First received: December 9, 2010
• Last updated: January 27, 2014
• Start date: December 2010
• Est. completion date: September 2012

Study information

• Verified date: January 2014
• Source: Proto Pharma Ltd
• Contact: n/a
• Is FDA regulated: No
• Health authority: Rwanda: Ethics CommitteeGhana : Food and Drugs BoardBurkina Fasu: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate that ArTiMist (sublingual artemether spray) is better than intravenous quinine in reducing parasite counts by >= 90% within 24 hours after the start of treatment in children with severe malaria, or uncomplicated malaria with gastrointestinal complications

Description:

Malaria causes significant morbidity and mortality in children in developing countries, despite the availability of highly effective antimalarial therapy. One of the key contributing factors is the delay in the initiation of treatment.

ArTiMist is a sublingual formulation of the established antimalarial treatment, artemether. In previous studies good bioavailability has been demonstrated. In an exploratory study (ART003) ArTiMist demonstrated a non statistically significant improvement of 26% (when compared to intravenous quinine) in the numbers of patients experiencing a parasite reduction of >= 90% within 24 hours of the initiation of treatment.

This Phase 3 study is being conducted to establish whether treatment with ArTiMist in children with severe falciparum malaria or uncomplicated falciparum malaria with gastrointestinal complications is at least 20% superior in providing parasitological success (defined as >= 90% reduction in parasite count at 24 hours after start of treatment) when compared to intravenous quinine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 151
• Est. completion date: September 2012
• Est. primary completion date: August 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. The patient's legally acceptable representative has provided informed consent and the patient has assented (where relevant) to participation in the trial

2. The patient is a child that weighs between 5.00 kg and 15.00 kg inclusive

3. The patient has falciparum malaria as evidenced by thick or thin blood smears of = 500 P Falciparum per mcl (patients with mixed infections may be included provided = 500 P Falciparum per mcl)

4. The patient has either:

• severe or complicated falciparum malaria as determined by the investigator based on the WHO criteria for severity, and/or

• uncomplicated falciparum malaria but is unable to tolerate oral medication as a result of gastrointestinal complications such as vomiting or diarrhoea.

Exclusion Criteria:

1. The patient's legally acceptable representative does not provide informed consent for participation, or the child if capable, does not assent to participation in the trial.

2. Ability to tolerate oral therapy

3. Patient has received any antimalarial therapy within the 7 days prior to first study drug administration.

4. Patient has evidence of significant co-infections (this does not include mixed Plasmodium infections).

5. Patient has a contraindication, allergy or is otherwise intolerant to either artemether or quinine .

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Malaria
• Malaria, Falciparum
• Plasmodium Falciparum Malaria

Intervention

Drug:
• Artemether Sublingual Spray
Artemether sublingual spray administered at 3 mg/kg (milligrams per kilogram) at specified timepoints
• Quinine
Quinine administered intravenously, 20 mg/kg loading dose followed by 10 mg/kg every eight hours

Locations

Country	Name	City	State
Burkina Faso	Centre National de Recherche et de Formation sur le Paludisme (CNRFP)	Ouagadougou
Ghana	Navrongo Health Research Centre	Navrongo
Rwanda	Rwinkwavu District Hospital	Rwinkwavu	Eastern Province

Sponsors (1)

Lead Sponsor	Collaborator
Proto Pharma Ltd

Countries where clinical trial is conducted

Burkina Faso,  Ghana,  Rwanda, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Parasitological Success (MITT)	Parasitological success defined as a reduction in parasite count of = 90% of baseline at 24 hours after the first dose	24 hours after start of treatment	No
Primary	Parasitological Success (PP)	Parasitological success defined as a reduction in parasite count of = 90% of baseline at 24 hours after the first dose	24 hours after start of treatment	No
Secondary	Parasite Clearance Time (PCT) [MITT Population]	Parasite clearance time (PCT). Time in hours from the initiation of therapy until the first of two successive parasite negative smears (zero parasite counts) are obtained	28 days after start of treatment	No
Secondary	PCT 90 [MITT Population]	Time for parasite counts to fall by 90%	28 days after start of treatment	No
Secondary	PCT 50 [MITT Population]	Time for parasite counts to fall by 50%	28 days after start of treatment	No
Secondary	PRR 24 [MITT Population]	The percentage reduction in parasite counts 24 hours after first dose	28 days after start of treatment	No
Secondary	PRR 12 [MITT Population]	The percentage reduction in parasite counts 12 hours after first dose	28 days after start of treatment	No
Secondary	Fever Clearance Time (FCT)	Time in hours from the initiation of therapy until the disappearance of fever (tympanic temperature < 38.0) that lasted at least 24 hours.	28 days after start of treatment	No
Secondary	Complete Cure Rate	The complete resolution of clinical signs and symptoms, malaria-related laboratory abnormalities, and elimination of asexual parasites by Day 7, with no recurrence up to Day 28 (+/- 2 days), and the 48h parasite count to be < 25% of baseline with no clinical deterioration	28 days after the start of treatment	No
Secondary	Early Treatment Failure	Early treatment failure is indicated by one or more of the following: Parasite count on Day 2 > Day 0, irrespective of temperature; Parasite count on Day 3 > 0 with tympanic temperature = 38.0°C; Parasite count on Day 3 = 25% of baseline; Administration of rescue antimalarial treatment	Three days after the start of treatment	No
Secondary	Late Clinical Failure	Signs of severe malaria on any day between Day 4 and Day 28 in the presence of parasitaemia, without previously meeting any of the criteria of early treatment failure; Presence of parasitaemia and tympanic temperature = 38.0°C (or history of fever), on any day between Day 4 and Day 28, without previously meeting any of the criteria of early treatment failure	28 days after the start of treatment	No
Secondary	Late Parasitological Failure	o Parasitaemia on any day from Day 7 to Day 28 and tympanic temperature = 38.0°C	28 days after the start of treatment	No
Secondary	Time to Return to Full Consciousness	Time in hours to return to full consciousness (Blantyre Coma Scale = 5), if level of consciousness is reduced (Blantyre Coma Scale <5) prior to dosing or within 24hours of first dosing.; For the Blantyre Coma Scale; Total - maximum 5, eye movement - maximum 1, best motor response - maximum 2, best verbal response - maximum 2	28 days after start of treatment	No
Secondary	Time to Return to Normal Per os Status	Time in hours to return to normal per os status. Normal per os was when the investigator considered the patient to be able to eat and drink normally.	28 days after start of treatment	No
Secondary	Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events, of Possible, Probably and Definite Causalities		28 days after start of treatment	Yes
Secondary	Number of Deaths or Neurological Sequelae at Day 28		28 days after start of treatment	Yes